Astrana Health
ASTH Nasdaq· Health Care Facilities
Last close · Oct 27, 2026
$36.94
KIRA · Stoqly’s AI analyst, in plain words
- Astrana Health had $3.2B of revenue in fiscal 2025, up 56.4% on the year before. Over five years, revenue changed +35.9% a year on average.
- Its operating margin was 2.5%, down 1.9 pts: of every 100 in sales, about 2 is left after running the business.
- Astrana Health made $22.5M of net profit in fiscal 2025. From fiscal 2017 to 2025, diluted EPS grew −8.0% a year.
- Free cash flow was $104M in fiscal 2025, 3.3% of revenue.
- Astrana Health returned $33.5M to shareholders in fiscal 2025, 32% of free cash flow. The diluted share count rose 2.9%.
- Astrana Health owes $609M more than it holds in cash, about 4.9 years of operating profit.
Market cap
$1.8B
P/E
44.5x
Revenue
$3.2B
Net income
$22.5M
Free cash flow
$104M
Operating margin
2.5%
Astrana Health in 30 seconds · fiscal 2025
Are sales growing?
+56.4%
Yes. Sales grew 56.4% last year.
Does it make a profit?
0.7%
A little. It keeps 0.7% of every sale as profit.
Does profit turn into cash?
3.3%
Partly. 3.3% of sales ends up as free cash.
Is debt under control?
4.9x
Heavy. Repaying its debt would take 4.9 years of operating profit.
How healthy are the accounts?
4 / 8
Mixed. It passes 4 of 8 health tests.
How is the share priced?
44.5x
One share costs 44.5 times its yearly profit per share. Typical for its sector: 27.9x.
What Astrana Health does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 12, 2026
- Legal name
- Astrana Health, Inc.
- CIK
- 0001083446
Astrana Health · ASTH
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $774M | $1.1B | $1.4B | $2.0B | $3.2B |
| Revenue growth | 12.6% | 47.8% | 21.2% | 46.7% | 56.4% |
| Gross margin | 23.0% | — | — | — | — |
| Operating margin | 12.7% | 9.1% | 6.1% | 4.4% | 2.5% |
| Net income | $68.9M | $45.2M | $60.7M | $43.1M | $22.5M |
| Net margin | 8.9% | 4.0% | 4.4% | 2.1% | 0.7% |
| Diluted EPS | $1.52 | $0.99 | $1.29 | $0.90 | $0.46 |
| Cash | |||||
| Cash from operations | $70.3M | $82.1M | $68.2M | $52.2M | $115M |
| Capital expenditure | $19.2M | $22.9M | $28.5M | $8.0M | $10.1M |
| Free cash flow | $51.1M | $59.2M | $39.7M | $44.2M | $104M |
| FCF margin | 6.6% | 5.2% | 2.9% | 2.2% | 3.3% |
| Dividends paid | $31.1M | $14.0M | $62.1M | $4.0M | $7.9M |
| Share buybacks | $5.7M | $9.2M | $10.2M | $0.9M | $25.6M |
| Share count change | 21.2% | 0.4% | 2.9% | 2.2% | 2.9% |
| Debt and strength | |||||
| Cash and short-term investments | $287M | $294M | $296M | $291M | $430M |
| Debt incl. finance leases | $185M | $206M | $280M | $436M | $1.0B |
| Shareholders' equity | $448M | $543M | $614M | $713M | $779M |
| Net debt / EBITDA | −0.9x | −0.7x | −0.2x | 1.2x | 4.9x |
| Current ratio | 3.5x | 2.9x | 2.1x | 1.8x | 1.4x |
| Interest coverage | 18.2x | 13.2x | 5.3x | 2.7x | 1.6x |
| Returns and quality | |||||
| Return on capital | 17.6% | 13.6% | 10.3% | 7.6% | 4.2% |
| Return on equity | 17.7% | 9.1% | 10.5% | 6.5% | 3.0% |
| Piotroski F-score | 8 | 4 | 5 | 4 | 4 |
| Altman Z'' | 4.8 | 4.6 | 4.4 | 3.4 | 1.9 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Astrana Health · ASTH
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
Similar companies
Each company’s latest fiscal year. Fiscal years end in different months, so periods don’t line up exactly.
| Company | Market cap | Growth | Op. margin | FCF margin | ROIC | P/E | F-score |
|---|---|---|---|---|---|---|---|
| Astrana Health ASTH | $1.8B | 56.4% | 2.5% | 3.3% | 4.2% | 44.5x | 4 |
| Acadia Healthcare ACHC | $2.7B | 5.0% | — | −13.3% | −16.0% | — | 4 |
| Ensign Group ENSG | $10.1B | 18.7% | 8.4% | — | 19.7% | 26.6x | 6 |
| Option Care Health OPCH | $5.0B | 13.0% | 6.0% | 3.8% | 11.4% | 24.4x | 5 |
| Encompass Health EHC | $12.2B | 10.5% | — | 7.4% | 15.8% | 19.8x | 8 |
Price compared with profit (P/E)
How many times its yearly profit per share one share costs. Higher means investors pay more for each unit of profit.
KIRA
At $36.94 a share, the company is worth $1.8B: 44.5 times its earnings of the last four quarters.
Astrana Health grew sales faster than 4 of its 4 similar companies. Its P/E is higher than 3 of 3.
Source: SEC EDGAR XBRL filings (CIK 0001083446). Data updated October 22, 2026. For information only — not investment advice. Check the original filings before relying on any figure.